Results 71 to 80 of about 164 (107)

Exploring the dual role of fumarate as an intracellular and extracellular hypoxia-induced signalling molecule

Myocardial ischemia is characterised by a restriction in blood flow to the heart, which limits nutrient and oxygen supply and removal of waste products. In healthy hearts, ischemia triggers a cardiac metabolic shift from oxidative metabolism to anaerobic
Castro Guarda, Marcos Felipe
core   +1 more source

Development and Validation of UV Method for the Estimation of Diroximel fumarate in Bulk and Tablet Dosage Form

Abstract Diroximel fumarate, sold under the brand name Vumerity, is a medication used for the treatment of relapsing forms of multiple sclerosis (MS). It acts as an immunosuppressant and anti-inflammatory drug. Diroximel fumarate is hypothesized to regulate cell signalling pathways, causing beneficial immune and neuroprotective effects.
Mohammad Atika Afreen Shafi, Narender Boggula, K Ratna Jyothi, Sreelatha Gangu   +3 more
openaire   +1 more source

Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis [PDF]

Background: In recent years a broader range of immunomodulatory and immunosuppressive treatment options have emerged for people with progressive forms of multiple sclerosis (PMS).
Ridley B., Peryer G., Gonzalez-Lorenzo M., Piggott T., Filippini G., Del Giovane C., Foschi M., Minozzi S., Tramacere I., Baldin E., Nonino F.   +10 more
core   +1 more source

Diroximel Fumarate

American Journal of Health-System Pharmacy, 2020
openaire   +1 more source

Fumarate Prodrugs as a Novel Therapeutic Approach in Acute Myeloid Leukaemia [PDF]

Fumarate Prodrugs as a Novel Therapeutic Approach in Acute Myeloid Leukaemia Majed Hussain A Alzamanan Submitted in partial fulfilment of the requirements of the Degree of Doctor of Philosophy This work was supported by Saudi Arabia Cultural Bureau in ...
Alzamanan, M
core  

Comparative Effectiveness of Diroximel Fumarate vs. Dimethyl Fumarate in Persons with Multiple Sclerosis: A US Claims Analysis of Relapse Outcomes

Advances in Therapy
Daniel Bandari, Devon Conway, Liang Dong, Nicholas Hong, Minxing Li, Anne Littlewood, Mike Roy, Sam Ulin, Chencan Zou, Babak Amerian-Williams, Nicholas Belviso, James B. Lewin, Jason P. Mendoza, Mirla Avila   +13 more
openaire   +1 more source

Diroximel fumarate for multiple sclerosis.

Australian prescriber
openaire   +1 more source

Electrochemical detection of diroximel fumarate using an α-cyclodextrin-based molecularly imprinted polymer sensor in human serum

International Journal of Electrochemical Science
Mahmoud Roushani, Zahra Mirzaei Karazan, Husam Jalil Abdulkahim   +2 more
openaire   +1 more source

Diroximel Fumarate in the Treatment of Multiple Sclerosis [PDF]

Neurodegenerative Disease Management, 2020
Diroximel fumarate (DRF) is a new emerging therapy for patients with multiple sclerosis. The levels of its active metabolite, monomethyl fumarate, are bioequivalent to the levels generated from dimethyl fumarate (DMF) treatment. The efficacy and safety profiles of DRF are expected to be similar to the well-established profiles of DMF. The metabolism of
Elise Jonasson, Tobias Sejbaek
exaly   +8 more sources

Descriptive Analysis of Patients Treated with Diroximel Fumarate and Dimethyl Fumarate—A Real-Life Experience

Journal of Personalized Medicine
Background: Dimethyl fumarate (DMF) and diroximel fumarate (DRF) are two treatments used for multiple sclerosis (MS) that have been shown to be effective in controlling MS patients. DRF was introduced in 2019 with the aim of decreasing the gastrointestinal side effects caused by DMF. Few real-life studies verify the data provided in the clinical trials.
Marina Blanco-Ruiz, Maria Luisa Ruiz-Franco   +1 more
exaly   +4 more sources